Chromis Therapeutics Inc., a San Diego, CA-based antiviral drug discovery company, completed the initial round of $3M seed financing.
The round was led by Torrey Pines Investment.
Led by Vadim Bichko, Ph.D., CSO and Scientific Founder, Chromis Therapeutics focuses on the development of novel curative treatments for chronic HBV infection using its proprietary drug design and discovery platform to advance multiple drug candidates to the clinic.
The company intends to use the funds to advance its platform of antiviral drugs, including cccDNA inhibitors, entry inhibitors and capsid assembly inhibitors, for the treatment of the Hepatitis B virus (HBV).
Chromis’ antiviral drugs have a novel target – HBV cccDNA (covalently closed circular DNA), whose formation and recycling are central to establishing and maintaining persistent infection, limiting efficacy of current antiviral treatments, as those drugs do not directly target cccDNA. The comoany’s leading HBV program is using its proprietary in vitro HBV core assembly model to discover and develop small molecules that reduce or eliminate HBV cccDNA from the nuclei of infected liver cells and block the mechanisms of their re-infection.